Early Watch: Veru Inc. (NASDAQ: VERU) Jumps To The Top Of Our Watchlist Following Coverage Announcement

*Sponsored Market Crux Initiates Coverage On Veru Inc. (NASDAQ: VERU) For Today 4/1/2025! Here’s What We Can Tell You—So Far… Four Firms Have Issued Targets Ranging From 308% To 716% Above Current Levels. Positioned In A Segment Forecast To Grow Over 900% And  Surpass $470B In Scale. Phase 2b Data Shows Preservation Of Muscle And Improved Body Composition. Well-Known Industry Vetaran—Dr. Phillip Frost Holds 5M Shares And Brings A $2B+ Healthcare Track Record. Get Veru Inc. (NASDAQ: VERU) On Your Screen While It’s Still Early… April 1, 2025 Dear Reader, Veru Inc. (NASDAQ: VERU) has landed at the top of our Tuesday watchlist. And here’s why… This company is advancing in a space projected to exceed $470B in value—with sector-wide expansion forecasts reaching 900%+ within the next 7 to 8 years. That kind of growth is rare.  But what’s even more rare?  Finding a little-known company in the early stages of that transformation—with institutional coverage, strategic backing, and data already in hand. Analyst Targets Suggest the Market May Be Behind… Veru Inc. (NASDAQ: VERU) has recently attracted new coverage from four institutional firms. And the price targets they’ve issued are hard to ignore: B. Riley Financial: $2 target (308% potential upside.) H.C. Wainwright & Co.: $2.50 target (410% potential upside.) Raymond James: $3 target (512% potential upside.) Oppenheimer: $4 target (716% potential upside.) That level of alignment doesn’t happen unless something has shifted—and in Veru’s case, it clearly has. Strategic Stakeholder Adds Weight to the Story… Dr. Phillip Frost—well known for helping build Key Pharmaceuticals and Ivax—has taken a significant stake in Veru Inc. (NASDAQ: VERU), securing over 5M shares. With a net worth exceeding $2B, his record of identifying companies with long-term clinical traction speaks for itself.  This isn’t just a passive “nobody” move—it’s a high-conviction signal from someone who’s been here before. What Veru Inc. (NASDAQ: VERU) Is Advancing—And Why It Matters… At the center of Veru Inc. (NASDAQ: VERU)’s pipeline is Enobosarm, a compound that targets body composition by reducing fat mass while preserving muscle—a meaningful approach, particularly for patients managing chronic illness or age-related conditions. In the company’s Phase 2b QUALITY trial, Enobosarm was tested alongside standard metabolic therapy and delivered results that stood out: - Preservation of lean muscle - Reduction in fat mass - Improvement across key clinical markers of body composition That alone is worth a closer look. But now, Veru Inc. (NASDAQ: VERU) is preparing for a pivotal Phase 3 trial, with FDA oversight already in motion—putting it in a development stage that many never reach. This next step isn’t just about clinical advancement—it’s about validation.  A successful Phase 3 outcome could elevate Enobosarm from promising candidate to potential cornerstone in a fast-emerging care model. With growing recognition from major firms, strategic backing already in place, and a market that’s scaling faster than most can keep up with, momentum may already be building beneath the surface. Here’s Why Veru Inc. (NASDAQ: VERU) Is Topping Our  Watchlist This Morning… 1. Strong Analyst Coverage: Four firms, four targets—all pointing to significant potential upside from current levels, like 308%, 410%, 512%, and even 716%. 2. Sector Tailwind: Veru Inc. (NASDAQ: VERU) is positioned in a segment forecast to grow by more than 900% and exceed $470B in size. 3. Encouraging Phase 2b Data: Clinical results show promise in preserving muscle while improving body composition. 4. Strategic Stake From a $2B+ Healthcare Leader: Dr. Phillip Frost’s 5M share position adds long-term weight. 5. Backed For Development: Veru holds over $26M in ca-sh and equivalents—giving it flexibility to advance without near-term financing pressure. The Bottom Line… Veru Inc. (NASDAQ: VERU) is quietly checking off all the boxes. It has respected coverage. It has long-term backing. With FDA oversight already in motion. And it’s operating in a sector that’s scaling fast. We have (VERU) at the top of our screens right now. Make sure you take a closer look at (VERU) while it’s still early. Several analysts have targets on (VERU) suggesting triple-digit upside potential—and it’s topping our watchlist today.  My next update should be on its way to you shortly—it could be here within the hour. Sincerely, Gary Silver Managing Editor, MarketCrux MarketCrux.com (“MarketCrux” or “MC” ) is owned by Headline Media LLC, a multi member limited liability company. Data is provided from third-party sources and MarketCrux is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MC brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owners of Headline Media LLC own and operate marketcrux . com (“MC”). From time to time, MC will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: marketcrux.com/disclaimer/  *Pursuant to an agreement between Headline Media LLC and TD Media LLC, Headline Media LLC has been hired for a period beginning on 03/17/2025 and ending on 04/01/2025 to publicly disseminate information about (VERU:US) via digital communications. Under this agreement, Headline Media LLC has been paid ten thousand USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Headline Media LLC, TD Media LLC and their member own shares of (VERU:US). Please see important disclosure information here: https://marketcrux.com/disclosure/veru/#details

Headline Media | 7901 4th Street N Suite 300 | St. Petersburg, FL 33702 US Unsubscribe | Update Profile | Constant Contact Data Notice